论文部分内容阅读
紧接着诺瓦蒂公司声称为乙酰胆碱酯酶抑制剂雷伐斯的明（ｒｉｖａｓｔｉｇｍｉｎｅ）的全球试验而征求轻度认知损害病人之后，美国国立老年病研究所设立基金，研究卫材／辉瑞公司的乙酰胆碱酯酶抑制剂Ａｒｉｃｅｐｔ对这种病人的效果。该项名为阿尔茨海默病的合作研究将在该所?
Immediately after Novartis claimed to be a global cognitive trial of rivastigmine, an acetylcholinesterase inhibitor, to patients with mild cognitive impairment, the National Institute of Geriatrics established a fund to study the use of Eisai / Pfizer Effect of acetylcholinesterase inhibitor Aricept on this patient. The joint research project called Alzheimer’s disease will be at the institute?